Nonalcoholic Fatty Liver Disease and Cardiovascular Risk

Nonalcoholic Fatty Liver Disease and Cardiovascular Risk: Translational Implications for Clinical Practice in 2021

In this presentation we will discuss the physiological changes of the heart in NAFLD/NASH patients, describe cardiac outcomes in NAFLD patients, and evaluate approaches to targeting cardiovascular risk in NASH clinical trials. We will also consider how our current knowledge of cardiovascular risk in NAFLD/NASH may potentially impact clinical practice in 2021.

Speaker:

Lisa B. VanWagner, MD, MSc, FAST, FAHA
Assistant Professor of Medicine-Gastroenterology & Hepatology and Preventive Medicine-Epidemiology
Comprehensive Transplant Center
Northwestern University Feinberg School of Medicine

Dr. Lisa VanWagner is an Assistant Professor of Medicine and Preventive Medicine in the Division of Gastroenterology & Hepatology at Northwestern. Her research utilizes human population-based approaches, large electronic health record data analysis and health services research methods to define and characterize cardiometabolic disease risk prediction, prevention and treatment approaches in patients with chronic liver disease. Her scientific work has been recognized by leading professional organizations, with awards from the American Association for the Study of Liver Diseases (AASLD), European Association for the Study of the Liver (EASL), American Society of Transplantation (AST) and American Heart Association (AHA). Clinically, she sees patients in the Northwestern Fatty Liver Clinic within the Digestive Health Center and the Liver Transplant Clinic with a specific interest in diseases affecting the heart-liver axis.

This webinar is part of the Translational Applications in Public Health mini-series, which is a collaboration between the Institute for Public Health and Medicine (IPHAM) and the Northwestern University Clinical and Translational Sciences (NUCATS) Institute.

For more information about IPHAM, visit: https://www.feinberg.northwestern.edu...